What’s the current market cap for Cogent Biosciences stock?

Cogent Biosciences (COGT) has a market cap of $5.9B as of June 03, 2026.

What is the P/E ratio for Cogent Biosciences stock?

The price to earnings (P/E) ratio for Cogent Biosciences (COGT) stock is 0 as of June 03, 2026.

Does Cogent Biosciences stock pay dividends?

No, Cogent Biosciences (COGT) stock does not pay dividends to its shareholders as of June 03, 2026.

When is the next Cogent Biosciences dividend payment date?

Cogent Biosciences (COGT) stock does not pay dividends to its shareholders.

What is the beta indicator for Cogent Biosciences?

Cogent Biosciences (COGT) has a beta rating of 0.37. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Cogent Biosciences stock | $COGT Share Price

About Cogent Biosciences

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

Ticker

$COGT

Sector

Health

Primary listing

NASDAQ

Employees

258

Headquarters

Waltham, United States

Website

www.cogentbio.com

COGT Metrics

BasicAdvanced

$5.9bn

-

-$2.51

0.37

-

What the Analysts think about COGT

Analyst ratings (Buy, Hold, Sell) for Cogent Biosciences stock.

Bulls say / Bears say

The APEX Part 2 trial for bezuclastinib in 81 AdvSM patients showed a 57% overall response rate (ORR) per mIWG, and an 80% ORR using PPR criteria. Additionally, 89% of patients had a reduction of at least 50% in bone marrow mast cells, supporting an NDA submission in the first half of 2026.

In the SUMMIT Part 2 study, bezuclastinib delivered statistically significant improvements for NonAdvSM: 87.4% of patients saw at least a 50% reduction in serum tryptase, 75.6% in bone marrow mast cell burden, and 85.7% in KIT D816V VAF by week 24, demonstrating consistent efficacy.

The FDA has accepted the new drug application (NDA) for bezuclastinib combined with sunitinib in GIST under Priority Review, with a PDUFA date of November 30, 2026, after Phase 3 PEAK results showed a 50% reduction in progression risk (hazard ratio 0.50) and a median progression-free survival of 16.5 months compared to 9.2 months.

Operating expenses increased sharply to $103.6 million in Q1 2026 from $74.9 million in Q1 2025, resulting in a net loss of $97.4 million and signaling a faster rate of cash burn without any product revenue.

Aside from bezuclastinib, Cogent’s pipeline consists only of early-stage programs (CGT1815, CGT1145, CGT4255) that are either in Phase 1 or at the IND-enabling stage, making the company's value highly dependent on the success of its lead asset.

Cogent raised just $45.7 million through an at-the-market offering in Q1 2026 and issued inducement grants totaling 62,600 options and 48,600 RSUs, which could dilute shareholders before any significant commercial revenue is generated.

Data summarised monthly by Lightyear AI. Last updated on 30 May 2026.

COGT Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

COGT Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

COGT News

AllArticlesVideos

Cogent Biosciences, Cigna Group among top healthcare stocks, according to UBS analysts

Proactive Investors·2 months ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

About Cogent Biosciences

Ticker

Employees

COGT Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about COGT

Analyst Ratings

Bulls say / Bears say

COGT Financial Performance

Income Statement

COGT Earnings Performance

Earnings per share (EPS)

COGT News

Cogent Biosciences, Cigna Group among top healthcare stocks, according to UBS analysts

Buy $COGT

Upcoming events

No upcoming events

Lightyear

Legal

Work with us

Bulls say / Bears say

Cogent Biosciences/$COGT

About Cogent Biosciences

Ticker

Employees

COGT Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about COGT

Analyst Ratings

Bulls say / Bears say

COGT Financial Performance

Income Statement

COGT Earnings Performance

Earnings per share (EPS)

COGT News

Cogent Biosciences, Cigna Group among top healthcare stocks, according to UBS analysts

Buy $COGT

Upcoming events

No upcoming events

What’s the current market cap for Cogent Biosciences stock?

What is the P/E ratio for Cogent Biosciences stock?

Does Cogent Biosciences stock pay dividends?

When is the next Cogent Biosciences dividend payment date?

What is the beta indicator for Cogent Biosciences?

Bulls say / Bears say